DAMORA THERAPEUTICS INC (DMRA) Stock Price & Overview
NASDAQ:DMRA • US36322Q2066
Current stock price
The current stock price of DMRA is 25.09 USD. Today DMRA is up by 0.04%.
DMRA Key Statistics
- Market Cap
- 1.511B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -17.62
- Dividend Yield
- N/A
DMRA Stock Performance
DMRA Stock Chart
DMRA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to DMRA.
DMRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DMRA. DMRA has a great financial health rating, but its profitability evaluates not so good.
DMRA Earnings
DMRA Forecast & Estimates
10 analysts have analysed DMRA and the average price target is 44.88 USD. This implies a price increase of 78.88% is expected in the next year compared to the current price of 25.09.
DMRA Groups
Sector & Classification
DMRA Financial Highlights
Over the last trailing twelve months DMRA reported a non-GAAP Earnings per Share(EPS) of -17.62. The EPS increased by 51.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.54% | ||
| ROE | -87.29% | ||
| Debt/Equity | 0 |
DMRA Ownership
DMRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DMRA
Company Profile
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Copenhagen, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2020-10-29. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. The company is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Company Info
IPO: 2020-10-29
DAMORA THERAPEUTICS INC
75 State Street, Suite 100
Copenhagen MASSACHUSETTS US
Employees: 5
Phone: 13026587581
DAMORA THERAPEUTICS INC / DMRA FAQ
What does DAMORA THERAPEUTICS INC do?
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Copenhagen, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2020-10-29. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. The company is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
What is the stock price of DAMORA THERAPEUTICS INC today?
The current stock price of DMRA is 25.09 USD. The price increased by 0.04% in the last trading session.
Does DMRA stock pay dividends?
DMRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of DMRA stock?
DMRA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting DMRA stock to perform?
10 analysts have analysed DMRA and the average price target is 44.88 USD. This implies a price increase of 78.88% is expected in the next year compared to the current price of 25.09.
Can you provide the sector and industry classification for DAMORA THERAPEUTICS INC?
DAMORA THERAPEUTICS INC (DMRA) operates in the Health Care sector and the Biotechnology industry.
What is the ownership structure of DAMORA THERAPEUTICS INC (DMRA)?
You can find the ownership structure of DAMORA THERAPEUTICS INC (DMRA) on the Ownership tab.